LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

Search

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

178.26 -0.28

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

176.16

Massimo

178.28

Metriche Chiave

By Trading Economics

Entrata

2.9M

56M

Vendite

-27M

1B

P/E

Media del settore

592.3

79.874

EPS

2.43

Margine di Profitto

5.529

Dipendenti

18,700

EBITDA

-23M

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+7.71% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-414M

8.4B

Apertura precedente

178.54

Chiusura precedente

178.26

Notizie sul Sentiment di mercato

By Acuity

9%

91%

9 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

28 nov 2025, 15:29 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

China's Jiangxi Copper Rejected by SolGold in $1 Billion Takeover Approach

28 nov 2025, 21:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

28 nov 2025, 19:59 UTC

Discorsi di Mercato

Oil Futures Settle Lower in Slow Black Friday Trade -- Market Talk

28 nov 2025, 19:47 UTC

Discorsi di Mercato

U.S. Natural Gas Lifted By Cold Weather Outlook -- Market Talk

28 nov 2025, 18:16 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

28 nov 2025, 18:16 UTC

Discorsi di Mercato

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28 nov 2025, 18:08 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

28 nov 2025, 18:08 UTC

Discorsi di Mercato

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28 nov 2025, 17:48 UTC

Discorsi di Mercato

Bank of Canada May Revise Up Inflation Projections After GDP Data -- Market Talk

28 nov 2025, 17:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

28 nov 2025, 16:50 UTC

Acquisizioni, Fusioni, Takeovers

Week's Best: Sieg's Stature at Citi Grows -- Barrons.com

28 nov 2025, 15:51 UTC

Discorsi di Mercato

Canada Household Spending Edges Lower -- Market Talk

28 nov 2025, 15:33 UTC

Discorsi di Mercato

Crude Futures Gain as U.S. Market Reopens -- Market Talk

28 nov 2025, 15:21 UTC

Discorsi di Mercato

Gold Rises on U.S. Rate-Cut Bets After CME Outage -- Market Talk

28 nov 2025, 15:13 UTC

Discorsi di Mercato

Dollar Recovers Slightly as Investors Already Price in Fed Rate Cut -- Market Talk

28 nov 2025, 15:11 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

28 nov 2025, 15:11 UTC

Discorsi di Mercato

Canadian National Railway Showing Positive Trend Going Into 2026 -- Market Talk

28 nov 2025, 14:51 UTC

Discorsi di Mercato

Canada GDP Report Masks Fragile State of Economy -- Market Talk

28 nov 2025, 14:41 UTC

Discorsi di Mercato

Canada's GDP Level Pulled Higher by 'Eye-Opening' Revisions -- Market Talk

28 nov 2025, 14:37 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Rise As Temperatures Drop -- Market Talk

28 nov 2025, 14:33 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

28 nov 2025, 14:33 UTC

Discorsi di Mercato

Steep Import Drop Fuels Surprise Lift in Canada GDP -- Market Talk

28 nov 2025, 14:20 UTC

Discorsi di Mercato

Too Much Noise in Canada's Surprise 3Q GDP Gain -- Market Talk

28 nov 2025, 14:10 UTC

Discorsi di Mercato

Canadian Nowcast Came Closest to Predicting Surprise 3Q Strength -- Market Talk

28 nov 2025, 13:39 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

28 nov 2025, 13:39 UTC

Discorsi di Mercato

Canada Trade Data Could Face Larger-Than-Normal Revisions -- Market Talk

28 nov 2025, 13:36 UTC

Discorsi di Mercato

Canada's Economy Expands More Than Expected -- Market Talk

28 nov 2025, 13:29 UTC

Discorsi di Mercato

CME Outage Sowing Chaos Across Markets, Trade Nations Says -- Market Talk

28 nov 2025, 13:27 UTC

Discorsi di Mercato

Russia-Ukraine Peace Efforts to Have Little Impact on Oil Fundamentals -- Market Talk

28 nov 2025, 13:19 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

7.71% in crescita

Previsioni per 12 mesi

Media 192.73 USD  7.71%

Alto 225 USD

Basso 165 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

12 ratings

7

Acquista

5

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

9 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat